Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma

Table 3

Outcomes of patients who withdrew from treatment with GDB for reasons other than toxicity or progression (AWD = alive with disease; NED = no evidence of disease; DOD = died of disease).

	Time on treatment (months)	Best response (RECIST)	Maximal change of tumor (%)	Treatment after GDB	Pathology from surgery	Outcome
63 y male with recurrent UPS of thigh	1.4	PR	−39	Resection of local recurrence	Treatment effect but viable tumor	NED at 3.1 y
55 y female with recurrent UPS of thigh	2.1	SD	0	Limb perfusion and then surgery	30–40% necrosis and fibrosis	NED at 3.5 y
44 y female with angiosarcoma of vagina	3.0	PR	−63	Observation since biopsy showed no tumor	No tumor detected	NED at 1.3 y
55 y male with metastatic LMS	3.5	PR	−31	Resection of lung metastases	Necrosis and histiocytic infiltration (70%)	DOD at 1.4 y
50 y female with large pelvic (nonuterine) LMS	3.7	SD	−11	Evaluated for surgery but unresectable	N/A	AWD at 2.5 y
39 y male with metastatic LMS	4.2	SD	−15	Radio-frequency ablation of liver metastases	N/A	DOD at 2.4 y
69 y female with metastatic uterine LMS	4.5	SD	−24	Resection of pelvic metastases	Predominantly viable	AWD at 2.2 y
40 y male with metastatic UPS	4.6	PR	−32	Resection of lung metastases	Viable tumor	DOD at 1 y
52 y male with metastatic angiosarcoma	5.6	PR	−31	Resection of lung metastases	Viable but microscopic tumor	AWD at 11 m
56 y male with metastatic pleomorphic liposarcoma	7.0	SD	−30	Resection of solitary bone metastasis	>99% necrosis, rare viable cells	NED at 3.1 y
52 y male with metastatic LMS	8.4	PR	−32	Resection of lung metastases	95% treatment effect	AWD at 2.2 y
72 y female with metastatic UPS	8.9	PR	−55	Observation and then further chemotherapy	N/A	AWD at 2.6 y
57 y female with metastatic uterine LMS	11.4	PR	−43	Resection of lung metastases	30% treatment effect	DOD at 1.9 y